Specify a stock or a cryptocurrency in the search bar to get a summary
Chimeric Therapeutics Ltd
CHMChimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia. Address: 62 Lygon Street, Carlton, VIC, Australia, 3053
Analytics
WallStreet Target Price
0.88 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CHM
Dividend Analytics CHM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CHM
Stock Valuation CHM
Financials CHM
Results | 2019 | Dynamics |